Book description
A complete guide to the role of high-density lipoproteins (HDL) in
new and emerging therapies
With high-density lipoproteins (HDL) playing an increasing role in
cardiovascular disease prevention, there is a growing need for an
in-depth look at HDL and its clinical value. This book summarizes the
current state of knowledge in the field, providing for the first time
a comprehensive, systematic, stylistically coherent, and up-to-date
review of the composition, structure, heterogeneity, metabolism,
epidemiology, genetics, and function of HDL.
Divided into three main parts, High-Density Lipoproteins first
examines normal HDL particles, then describes defective HDL, and
finally addresses the therapeutic normalization of subnormal levels
and defective biological activities of this lipoprotein class. The
book highlights the functional properties of HDL, which are relevant
to the pathophysiology of atherosclerosis and thrombosis, and
discusses the compositional and metabolic heterogeneity of HDL
particles.
Readers will come away with a clear understanding of the role of HDL
in biological processes, the potential value of functional HDL as a
therapeutic target, and how current and emerging therapies are poised
to influence the treatment of heart disease in the future.
Anatol Kontush, BSc (Hons), PhD, is Research
Director at the Dyslipidemia and Atherosclerosis Research Unit of the
National Institute of Health and Medical Research (INSERM) at the
Pitié-Salpêtrière Hospital, Paris, France. An award-winning scientist,
Dr. Kontush has authored more than 100 original papers and book chapters.
M. John Chapman, BSc, PhD, DSc, FESC, is President of the
European Atherosclerosis Society and Director of the Dyslipidemia and
Atherosclerosis Research Unit of the National Institute of Health and
Medical Research (INSERM) at the Pitié-Salpêtrière Hospital in Paris,
France, affiliated with the medical faculty of the Pierre and Marie
Curie University, Paris. He has authored more than 400 articles and
book chapters.
